Neuropeptide Y fragments derived from neprilysin processing are neuroprotective in a transgenic model of Alzheimer's disease.
about
Neural stem/progenitor cells in Alzheimer's diseaseNeuropeptide Y: A stressful review.Neuregulin 1 improves cognitive deficits and neuropathology in an Alzheimer's disease model.Peripheral delivery of a CNS targeted, metalo-protease reduces aβ toxicity in a mouse model of Alzheimer's diseaseNeuropeptide Y protects rat cortical neurons against β-amyloid toxicity and re-establishes synthesis and release of nerve growth factorNeuropeptide Y-based recombinant peptides ameliorate bone loss in mice by regulating hematopoietic stem/progenitor cell mobilizationA neuroprotective brain-penetrating endopeptidase fusion protein ameliorates Alzheimer disease pathology and restores neurogenesis.Transgenic mice overexpressing amyloid precursor protein exhibit early metabolic deficits and a pathologically low leptin state associated with hypothalamic dysfunction in arcuate neuropeptide Y neuronsNeurodegeneration in a transgenic mouse model of multiple system atrophy is associated with altered expression of oligodendroglial-derived neurotrophic factors.Continuation of exercise is necessary to inhibit high fat diet-induced β-amyloid deposition and memory deficit in amyloid precursor protein transgenic miceNeuropeptide Y stimulates autophagy in hypothalamic neurons.Exercise is more effective than diet control in preventing high fat diet-induced β-amyloid deposition and memory deficit in amyloid precursor protein transgenic mice.Systemic Central Nervous System (CNS)-targeted Delivery of Neuropeptide Y (NPY) Reduces Neurodegeneration and Increases Neural Precursor Cell Proliferation in a Mouse Model of Alzheimer Disease.Neuropeptide Y receptors activation protects rat retinal neural cells against necrotic and apoptotic cell death induced by glutamate.Caloric restriction stimulates autophagy in rat cortical neurons through neuropeptide Y and ghrelin receptors activation.Gene therapy in Alzheimer's disease - potential for disease modificationMeta-analysis of synaptic pathology in Alzheimer's disease reveals selective molecular vesicular machinery vulnerability.Are amyloid-degrading enzymes viable therapeutic targets in Alzheimer's disease?Proteolytic degradation of amyloid β-protein.The effect of neuropeptide Y on cell survival and neurotrophin expression in in-vitro models of Alzheimer's disease.Adipokine pathways are altered in hippocampus of an experimental mouse model of Alzheimer's disease.NPY binds with heme to form a NPY-heme complex: enhancing peroxidase activity in free heme and promoting NPY nitration and inactivation.Long-term neprilysin inhibition - implications for ARNIs.Neuroprotective effect of neuropeptide Y against β-amyloid 25-35 toxicity in SH-SY5Y neuroblastoma cells is associated with increased neurotrophin production.Major amyloid-β-degrading enzymes, endothelin-converting enzyme-2 and neprilysin, are expressed by distinct populations of GABAergic interneurons in hippocampus and neocortex.NPY modulates miR-30a-5p and BDNF in opposite direction in an in vitro model of Alzheimer disease: a possible role in neuroprotection?The neuroprotective and neurogenic effects of neuropeptide Y administration in an animal model of hippocampal neurodegeneration and temporal lobe epilepsy induced by trimethyltin.
P2860
Q26738352-F53B8AA3-AF6C-41CC-BE58-6063AA5FCF78Q26781704-3CA05248-5FF5-4BE9-B459-A8FA5452A1CBQ27316651-E5268A7B-8D08-43CD-AA4F-2F16B9FCA226Q27437619-80B742CD-5DFE-4EEE-816C-0BB48ECB176CQ28570557-5CC15D37-7725-4BDE-84AD-E8AE7B83C9CCQ33649246-A9E7E48A-BC4A-417F-AB54-4B7DA86A1187Q33793059-4BC52175-89C2-42CF-84CD-8C018BB42D2CQ33832139-860BCAF2-CAEF-4310-B3EF-EBCDA9A5FF23Q33958289-501C4FB4-ECB6-4A86-A9ED-725705C6335EQ34984057-C83D1D13-8065-4E5F-BFBA-488E75EF1DAFQ35279368-5F955C06-9C6A-4EDE-806B-CBB537013278Q36080477-E16B3901-3906-469B-8EC0-4C65138A6C93Q36489317-6364CC3D-AE93-4DA3-A3AF-38D66736EBD4Q36907135-4D8B94CB-05E2-469C-8725-5C33BA9BF0CEQ37194243-81DE9952-24B9-4DE9-9220-67370E2694EDQ37295252-F28315EA-92EC-4BDA-A0E7-CEA01704A753Q37326829-1815CF99-8B94-48F5-939C-4B3E6143F565Q37961852-47BB7492-DEFC-4292-BC0E-25E2B8646F9CQ38016899-E6188BAB-D5BF-4F57-8DF3-768861EFAEC0Q38229754-0689A9A8-5900-431F-B847-D34722262D8BQ38300217-18BAF631-D07B-4898-A251-BCD61632147DQ38665001-5D988C1D-94D7-4183-93C4-D5BE2C8CC0E2Q39038686-B6AFCAC3-955B-48F9-B9BF-2C6F4602D137Q39586898-9CD74144-09F2-4443-8D72-7AE86AE7385CQ46152909-69CCB3C3-8677-4F61-970A-22E2DE3B88E9Q46161319-2B86B0D5-B893-42B0-BA40-2490C6D6CF6FQ47847624-E47A4488-B000-4B45-BC07-741C3A731DC0
P2860
Neuropeptide Y fragments derived from neprilysin processing are neuroprotective in a transgenic model of Alzheimer's disease.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Neuropeptide Y fragments deriv ...... model of Alzheimer's disease.
@en
Neuropeptide Y fragments deriv ...... model of Alzheimer's disease.
@nl
type
label
Neuropeptide Y fragments deriv ...... model of Alzheimer's disease.
@en
Neuropeptide Y fragments deriv ...... model of Alzheimer's disease.
@nl
prefLabel
Neuropeptide Y fragments deriv ...... model of Alzheimer's disease.
@en
Neuropeptide Y fragments deriv ...... model of Alzheimer's disease.
@nl
P2093
P2860
P1476
Neuropeptide Y fragments deriv ...... model of Alzheimer's disease.
@en
P2093
Anthony Adame
Brian Spencer
Fred H Gage
John B Rose
Leslie Crews
Louis B Hersh
Michael Mante
Rewati Potkar
Robert A Marr
P2860
P304
P356
10.1523/JNEUROSCI.4220-08.2009
P407
P577
2009-01-01T00:00:00Z